A Phase 3 interventional study of Placebo and SST-0225 Topical Ibuprofen Cream in Acute Ankle Sprain, sponsored by Strategic Science & Technologies, LLC. Completed at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-05-21.
Sponsored by Strategic Science & Technologies, LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,185 studies in Lymphoma, Follicular with a site in United States — 127 open to participants now, 216 under way, 20 of them phase 3. Lymphoma, Follicular · United States.
Among the 1,185 studies in Lymphoma, Follicular with a site in United States, this one is the 85th largest by enrollment of the 1,015 interventional ones that give a count, is one of 41 that started in 2013, is one of 105 in phase 3, and was the 677th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →127 of the 1,185 studies in Lymphoma, Follicular with a site in United States are open now. Recruiting first, the newest first:
University of California, Irvine · Sites in United States
Ages 18+ · Women only
University of Washington · Sites in United States
Ages 18+
Paolo Caimi, MD · Sites in United States
Ages 18+
Montefiore Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
New York State Psychiatric Institute · Sites in United States
Ages 22–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,185 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 499 · Phase 2 523 · Phase 3 113 · Phase 4 11
First in 1988; this study’s year is marked. 41 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 305 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 38 across the 1,015 interventional studies, 74 across the 62 observational. Of the 903 that completed or were terminated, 358 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
345 of 1,185 have an industry lead sponsor. The 10 most frequent:
Strategic Science & Technologies, LLC is the lead sponsor of 9 studies on the registry; none are open to participants now.
Strategic Science & Technologies, LLC has 1 study filed under Lymphoma, Follicular — fewer than ten, so there is no comparison to draw.
68 of the studies in Lymphoma, Follicular with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT04224493Phase 3Epizyme, Inc.A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | 2027-02-13 |
| NCT05688475Bristol-Myers SquibbA Rollover Study of CC-122 | 2026-11-30 |
| NCT00659035Asokumar BuvanendranUse of Driving Tests to Evaluate Patient Performance on Oral Opioids | 2026-12 |
| NCT06245031Cognito Therapeutics, Inc.Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015) | 2026-12 |
Add all 68 to your calendar (.ics) → With an account.
Among the 1,185 studies in Lymphoma, Follicular with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, multi-center, double-blind, placebo-controlled, multi-dose, parallel-group study. Approximately 300 subjects (150 per group) 16 years of age and older with a current (within 24 hours from Visit 1) Grade I or II ankle sprain, and who meet all eligibility criteria, will be randomized into the study and will receive either the active treatment (SST-0225 ibuprofen cream), or matching placebo. Subjects will apply an amount equivalent to a 4 inch line of investigational product to the affected ankle approximately every 4-6 hours. At Visit 1 two doses will be applied at the site. All subsequent doses of the investigational product will be applied every 4 to 6 hours with a total of 4 doses in a 24 hour period. Duration of treatment with the investigational product is 7 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Grade I or II acute ankle sprain injury within 24 hours prior to first use of product.
Females of must be willing to use an approved method of during study participation. Subjects currently using any of the below mentioned contraception methods, must have used the method for a minimum of three months prior to study enrollment, and must be willing to continue its use (at the same dose) throughout the study.
-
Exclusion Criteria:
Subjects meeting any of the following criteria will not be entered in the study:
Females who are pregnant or lactating.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SST-0225 Topical Ibuprofen Cream (investigational product) Dose: 2.7 grams of cream containing 200 mg ibuprofen
Drug: SST-0225 Topical Ibuprofen Cream
Placebo topical formulation (Reference product)
Drug: Placebo
Placebo cream
SST-0225 Topical Ibuprofen Cream
Also known as: Ibuprofen
24 Hour SPID
Tme weighted summed pain intensity on movement difference from baseline over the first 24 hours (SPID24) following the first application of study medication on Day 1
Time frame: 24 Hours
Time to onset of confirmed perceptible pain relief and onset of meaningful pain relief
• Time to onset of confirmed perceptible pain relief and onset of meaningful pain relief over the four-hour in-office phase of the study.
Time frame: First 4 hours
Mean change from baseline in subject reported pain intensity
• Mean change from baseline in subject reported pain intensity (at rest and on movement) and pain relief (on movement only) as assessed at 15 minutes, 30 minutes, and hourly up to 4 hours following the first application on Day 1.
Time frame: First 4 hours
Mean change from baseline in pain scores on movement
• Mean change from baseline in pain scores on movement at hours 6, 8, 10, 12, 20 and 24 hours over the first 24 hours.
Time frame: First 24 hours
Percent of subjects with > 15%, > 30% and > 50% reductions in pain intensity
• Percent of subjects with \> 15%, \> 30% and \> 50% reductions in pain intensity from baseline at 24 hours.
Time frame: First 24 hours
Subject's global evaluation of investigational product
• Subject's global evaluation of investigational product evaluated at Days 2, 4 and 7 (or End-of-Study) based on a 5 point scale.
Time frame: 7 days
Use of rescue medication including time to first use
• Use of rescue medication including time to first use (first 12 hours), proportion of subjects using rescue and amount of rescue medication used.
Time frame: 7 days
Change from baseline in pain scores on movement
• Change from baseline in pain scores on movement at time of each dose on Days 2-7.
Time frame: 7 days
Number and percent of patients with systemic and local (skin) self-reported adverse events
Number and percent of patients with systemic and local (skin) self-reported adverse events.
Time frame: 7 days
Ran from Jun 2013 to primary completion in Jan 2014, 7 months.
Of 45 industry-sponsored phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 86. This study's 7 months is below that.
Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen
Strategic Science & Technologies, LLC